Vivani Medical Mergers and Acquisitions Presentation Deck

Lead Product (NPM-119): 6-Month Exenatide (Glucagon-like Peptide 1 Receptor Agonist) Implant for Type 2 Diabetes 1 Guo 2016 2 Carls et al. 2017 3 MS 2013 Report • Non-adherence is the primary reason for low, real-world effectiveness¹.2 • Guaranteed adherence will produce significant healthcare cost savings³ • FDA indicated 505(b)(2) streamlined approval pathway may be available • ~$54M raised pre-merger from investors including AstraZeneca 11

View entire presentation